Erleada Approved in Europe to Treat Metastatic Hormone-sensitive Prostate Cancer

Erleada Approved in Europe to Treat Metastatic Hormone-sensitive Prostate Cancer
The European Commission (EC) has agreed to extend the use of Janssen’s Erleada (apalutamide) to treat men whose metastatic prostate cancer still responds to androgen deprivation therapy (ADT), a condition known as metastatic hormone-sensitive prostate cancer (mHSPC). The decision, which follows a positive recommendation issued earlier this month by a committee of the European Medicines Agency, is for a combination of Erleada and ADT. This combination was approved by the U.S. Food and Drug Administration for a similar indication in September. Findings from the double-blind TITAN Phase 3 trial (NCT02489318) — which supported both approvals — showed that the Erleada-ADT combination was significantly better than ADT alone at extending survival and delaying disease worsening in mHSPC patients. “Prostate cancer is the most prevalent for
Subscribe or to access all post and page content.